Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,664 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral placebo capsule Clear all
Completed Phase 2 Interventional

STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

NCT05843578
View directory record Official record
Conditions
Fibrostenotic Crohn's Disease
Interventions
AGMB-129, Placebo
Drug
Lead sponsor
Agomab Spain S.L.U.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Hamden, Connecticut • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

NCT04799158
View directory record Official record
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Anniston, Alabama • Athens, Alabama • Huntsville, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Developing a Mobile Method to Measure THC-induced Impairment

NCT03804840
View directory record Official record
Conditions
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 22, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

NCT07456696
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
TSND-201, Placebo
Drug
Lead sponsor
Transcend Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Pilot of Letrozole for Uterine Myomas

NCT02470741
View directory record Official record
Conditions
Leiomyoma, Uterine Fibroids
Interventions
Letrozole, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 22, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional Results available

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

NCT04372121
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
23
States / cities
Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

NCT04056195
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
SKI-O-703, Placebo oral tablet
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Durham, North Carolina • Greenville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 22, 2026, 2:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Prospective, Multi Centric, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KSM-66 Ashwagandha (Withania Somnifera) in Adults Experiencing High Stress and/or Anxiety

NCT05684991
View directory record Official record
Conditions
Anxiety, Stress
Interventions
KMS-66 Ashwagandha 300mg, placebo capsule
Dietary Supplement
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 22, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

NCT00874796
View directory record Official record
Conditions
HCV Infection
Interventions
GS-9450, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)

NCT03126227
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101, Placebo
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
62
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Study of Terazosin for Parkinson's Disease

NCT03905811
View directory record Official record
Conditions
Parkinson Disease
Interventions
Terazosin 5 MG, Placebo oral capsule
Drug
Lead sponsor
Jordan Schultz
Other
Eligibility
40 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study of Debio 1450 in Healthy Subjects

NCT02162199
View directory record Official record
Conditions
Bacterial Infections
Interventions
Debio 1450, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

NCT00587041
View directory record Official record
Conditions
Nephrolithiasis, Hyperoxaluria, Crohn's Disease
Interventions
Oxadrop, Agri-King Synbiotic (AKSB), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 22, 2026, 2:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea

NCT07577661
View directory record Official record
Conditions
Obstructive Sleep Apnea, Sleep-disordered Breathing
Interventions
Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition
Other · Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

NCT01530022
View directory record Official record
Conditions
Healthy
Interventions
Lacosamide (LCM), Carbamazepine Immediate Release (CBZ-IR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

NCT06017609
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
JTT-861 Capsules, Placebo Capsules
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Crystal River, Florida • Hialeah, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Trial of an Intervention to Improve Metformin Persistence and Adherence

NCT03467763
View directory record Official record
Conditions
Metformin Adverse Reaction, Tolerance
Interventions
Metformin Extended Release Oral Tablet, Placebo oral capsule
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2020 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

NCT01755455
View directory record Official record
Conditions
Cystic Fibrosis, Anemia, Iron-Deficiency
Interventions
Ferrous sulfate 325mg, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Portland, Maine • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and PK Study of OLT1177 Capsules

NCT02134964
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OLT1177 Capsules, Placebo Capsules
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

NCT05268016
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ME3183, Placebo
Drug
Lead sponsor
Meiji Pharma USA Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Rogers, Arkansas • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

NCT01964404
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
Interventions
Marijuana, Dronabinol, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
2
States / cities
Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 22, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

NCT03337308
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos
Combination Product · Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 22, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

NCT04590508
View directory record Official record
Conditions
Crohn Disease
Interventions
Xanthohumol, Placebo
Drug · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 22, 2026, 2:42 AM EDT